Promising role of Toll-like receptor 8 agonist in concert with prostratin for activation of silent HIV

Journal of Virology

Volumn 91, Issue 4, 2017, Pages

  Rochat, M A ^a   Schlaepfer, E ^a   Speck, R F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Aviremic patients; HIV cure; HIV 1; J lat cells; Latency reversing agents; Monocyte derived dendritic cells

Indexed keywords

ANTIVIRUS AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENHANCED GREEN FLUORESCENT PROTEIN; GLYCOGEN SYNTHASE KINASE 3; HLA DR ANTIGEN; INTERLEUKIN 12P70; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROSTRATIN; PROTEIN KINASE C INHIBITOR; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE 1; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL ESTER; PROTEIN KINASE C BETA; PROTEIN KINASE SYK;

ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CELL CONTACT; CELL INTERACTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; DRUG EFFICACY; GENE DOSAGE; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LONG TERMINAL REPEAT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION; ADULT; AGONISTS; ANIMAL; CD4 LYMPHOCYTE COUNT; CELL COMMUNICATION; CELL LINE; COCULTURE; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION; VIROLOGY; VIRUS LOAD;

ADULT; ANIMALS; CD4 LYMPHOCYTE COUNT; CELL COMMUNICATION; CELL LINE; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; PHORBOL ESTERS; PROTEIN KINASE C BETA; SYK KINASE; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 85011954105     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02084-16     Document Type: Article

References (129)

1. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188. https://doi.org/10.1038/387183a0.
2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300. https://doi.org/10.1126/science.278.5341.1295.
3. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94:13193-13197. https://doi.org/10.1073/pnas.94.24.13193.
4. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295. https://doi.org/10.1126/science.278.5341.1291.
5. Chun TW, Davey RT, Jr, Engel D, Lane HC, Fauci AS. 1999. Re-emergence of HIV after stopping therapy. Nature 401:874-875. https://doi.org/10.1038/44755.
6. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-517. https://doi.org/10.1038/8394.
7. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727-728. https://doi.org/10.1038/nm880.
8. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. 1998. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 95:8869-8873. https://doi.org/10.1073/pnas.95.15.8869.
9. Friedman J, Cho WK, Chu CK, Keedy KS, Archin NM, Margolis DM, Karn J. 2011. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol 85:9078-9089. https://doi.org/10.1128/JVI.00836-11.
10. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. 2006. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 25:139-149. https://doi.org/10.1038/sj.emboj.7600900.
11. Verdin E, Paras P, Jr, Van Lint C. 1993. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12:3249-3259.
12. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. 2009. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 5:e1000495. https://doi.org/10.1371/journal.ppat.1000495.
13. He G, Margolis DM. 2002. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol 22:2965-2973. https://doi.org/10.1128/MCB.22.9.2965-2973.2002.
14. Karn J. 2011. The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr Opin HIV AIDS 6:4-11. https://doi.org/10.1097/COH.0b013e328340ffbb.
15. Ganesh L, Burstein E, Guha-Niyogi A, Louder MK, Mascola JR, Klomp LW, Wijmenga C, Duckett CS, Nabel GJ. 2003. The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature 426: 853-857. https://doi.org/10.1038/nature02171.
16. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. 1995. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 9:2723-2735. https://doi.org/10.1101/gad.9.22.2723.
17. Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326: 711-713. https://doi.org/10.1038/326711a0.
18. Budhiraja S, Famiglietti M, Bosque A, Planelles V, Rice AP. 2013. Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells. J Virol 87:1211-1220. https://doi.org/10.1128/JVI.02413-12.
19. Zhou Q, Yik JH. 2006. The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol Mol Biol Rev 70:646-659. https://doi.org/10.1128/MMBR.00011-06.
20. Tyagi M, Pearson RJ, Karn J. 2010. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 84:6425-6437. https://doi.org/10.1128/JVI.01519-09.
21. Chiang K, Sung TL, Rice AP. 2012. Regulation of cyclin T1 and HIV-1 replication by microRNAs in resting CD4+ T lymphocytes. J Virol 86: 3244-3252. https://doi.org/10.1128/JVI.05065-11.
22. Hoque M, Shamanna RA, Guan D, Pe'ery T, Mathews MB. 2011. HIV-1 replication and latency are regulated by translational control of cyclin T1. J Mol Biol 410:917-932. https://doi.org/10.1016/j.jmb.2011.03.060.
23. Dar RD, Hosmane NN, Arkin MR, Siliciano RF, Weinberger LS. 2014. Screening for noise in gene expression identifies drug synergies. Science 344:1392-1396. https://doi.org/10.1126/science.1250220.
24. Deeks SG. 2012. HIV: shock and kill. Nature 487:439-440. https://doi.org/10.1038/487439a.
25. Kulkosky J, Sullivan J, Xu Y, Souder E, Hamer DH, Pomerantz RJ. 2004. Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. AIDS Res Hum Retroviruses 20:497-505. https://doi.org/10.1089/088922204323087741.
26. Hamer DH. 2004. Can HIV be cured? Mechanisms of HIV persistence and strategies to combat it. Curr HIV Res 2:99-111.
27. Olesen R, Vigano S, Rasmussen TA, Sogaard OS, Ouyang Z, Buzon M, Bashirova A, Carrington M, Palmer S, Brinkmann CR, Yu XG, Ostergaard L, Tolstrup M, Lichterfeld M. 2015. Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat. J Virol 89:10176-10189. https://doi.org/10.1128/JVI.01484-15.
28. Wren LH, Stratov I, Kent SJ, Parsons MS. 2013. Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses. Vaccine 31:5506-5517. https://doi.org/10.1016/j.vaccine.2013.08.035.
29. Lee WS, Parsons MS, Kent SJ, Lichtfuss M. 2015. Can HIV-1-specific ADCC assist the clearance of reactivated latently infected cells? Front Immunol 6:265. https://doi.org/10.3389/fimmu.2015.00265.
30. Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, Davey RT, Jr, Dybul M, Kovacs JA, Metcalf JA, Mican JM, Berrey MM, Corey L, Lane HC, Fauci AS. 1999. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 5:651-655. https://doi.org/10.1038/9498.
31. Stellbrink HJ, van Lunzen J, Westby M, O'Sullivan E, Schneider C, Adam A, Weitner L, Kuhlmann B, Hoffmann C, Fenske S, Aries PS, Degen O, Eggers C, Petersen H, Haag F, Horst HA, Dalhoff K, Mocklinghoff C, Cammack N, Tenner-Racz K, Racz P. 2002. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 16:1479-1487. https://doi.org/10.1097/00002030-200207260-00004.
32. Davey RT, Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, Natarajan V, Lempicki RA, Adelsberger JW, Miller KD, Kovacs JA, Polis MA, Walker RE, Falloon J, Masur H, Gee D, Baseler M, Dimitrov DS, Fauci AS, Lane HC. 1999. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 96:15109-15114. https://doi.org/10.1073/pnas.96.26.15109.
33. Nunnari G, Leto D, Sullivan J, Xu Y, Mehlman KE, Kulkosky J, Pomerantz RJ. 2005. Seminal reservoirs during an HIV type 1 eradication trial. AIDS Res Hum Retroviruses 21:768-775. https://doi.org/10.1089/aid.2005.21.768.
34. Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Chouraqui M, Pisapia M, Delbeke E. 2001. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. J Acquir Immune Defic Syndr 26:44-55.
35. Levy Y, Sereti I, Tambussi G, Routy JP, Lelievre JD, Delfraissy JF, Molina JM, Fischl M, Goujard C, Rodriguez B, Rouzioux C, Avettand-Fenoel V, Croughs T, Beq S, Morre M, Poulin JF, Sekaly RP, Thiebaut R, Lederman MM. 2012. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 55:291-300. https://doi.org/10.1093/cid/cis383.
36. Vandergeeten C, Fromentin R, DaFonseca S, Lawani MB, Sereti I, Lederman MM, Ramgopal M, Routy JP, Sekaly RP, Chomont N. 2013. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 121:4321-4329. https://doi.org/10.1182/blood-2012-11-465625.
37. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, Battaglia CA, Landay AL, Pahwa S, Fischl MA, Asmuth DM, Tenorio AR, Altman JD, Fox L, Moir S, Malaspina A, Morre M, Buffet R, Silvestri G, Lederman MM, ACTG 5214 Study Team. 2009. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 113: 6304-6314. https://doi.org/10.1182/blood-2008-10-186601.
38. van Praag RM, Prins JM, Roos MT, Schellekens PT, Ten Berge IJ, Yong SL, Schuitemaker H, Eerenberg AJ, Jurriaans S, de Wolf F, Fox CH, Goudsmit J, Miedema F, Lange JM. 2001. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol 21:218-226. https://doi.org/10.1023/A:1011091300321.
39. Shen X, Xiong GL, Jing Y, Xiao H, Cui Y, Zhang YF, Shan YJ, Xing S, Yang M, Liu XL, Dong B, Wang LS, Luo QL, Yu ZY, Cong YW. 2015. The protein kinase C agonist prostratin induces differentiation of human myeloid leukemia cells and enhances cellular differentiation by chemotherapeutic agents. Cancer Lett 356:686-696. https://doi.org/10.1016/j.canlet.2014.10.018.
40. Morgan RJ, Jr, Leong L, Chow W, Gandara D, Frankel P, Garcia A, Lenz HJ, Doroshow JH. 2012. Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California Cancer Consortium study. Invest New Drugs 30: 723-728. https://doi.org/10.1007/s10637-010-9557-5.
41. Gonelli A, Mischiati C, Guerrini R, Voltan R, Salvadori S, Zauli G. 2009. Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents. Mini Rev Med Chem 9:498-509. https://doi.org/10.2174/138955709787847967.
42. Jiang G, Dandekar S. 2015. Targeting NF-kappaB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. AIDS Res Hum Retroviruses 31:4-12. https://doi.org/10.1089/aid.2014.0199.
43. Biancotto A, Grivel JC, Gondois-Rey F, Bettendroffer L, Vigne R, Brown S, Margolis LB, Hirsch I. 2004. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 78:10507-10515. https://doi.org/10.1128/JVI.78.19.10507-10515.2004.
44. Brooks DG, Hamer DH, Arlen PA, Gao L, Bristol G, Kitchen CM, Berger EA, Zack JA. 2003. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19:413-423. https://doi.org/10.1016/S1074-7613(03)00236-X.
45. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR, Pomerantz RJ. 2001. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98:3006-3015. https://doi.org/10.1182/blood.V98.10.3006.
46. Wolschendorf F, Duverger A, Jones J, Wagner FH, Huff J, Benjamin WH, Saag MS, Niederweis M, Kutsch O. 2010. Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. J Virol 84:8712-8720. https://doi.org/10.1128/JVI.00523-10.
47. Martinez-Bonet M, Clemente MI, Alvarez S, Diaz L, Garcia-Alonso D, Munoz E, Moreno S, Munoz-Fernandez MA. 2015. Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal. Antiviral Res 123:163-171. https://doi.org/10.1016/j.antiviral.2015.09.014.
48. Diaz L, Martinez-Bonet M, Sanchez J, Fernandez-Pineda A, Jimenez JL, Munoz E, Moreno S, Alvarez S, Munoz-Fernandez MA. 2015. Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-kB-dependent mechanism. Sci Rep 5:12442. https://doi.org/10.1038/srep12442.
49. Pandelo Jose D, Bartholomeeusen K, da Cunha RD, Abreu CM, Glinski J, da Costa TB, Bacchi Rabay AF, Pianowski Filho LF, Dudycz LW, Ranga U, Peterlin BM, Pianowski LF, Tanuri A, Aguiar RS. 2014. Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology 462-463: 328-339. https://doi.org/10.1016/j.virol.2014.05.033.
50. Abreu CM, Price SL, Shirk EN, Cunha RD, Pianowski LF, Clements JE, Tanuri A, Gama L. 2014. Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One 9:e97257. https://doi.org/10.1371/journal.pone.0097257.
51. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, Verdin E, Greene WC. 2004. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 279:42008-42017. https://doi.org/10.1074/jbc.M402124200.
52. Sung TL, Rice AP. 2006. Effects of prostratin on cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells. Retrovirology 3:66. https://doi.org/10.1186/1742-4690-3-66.
53. Beans EJ, Fournogerakis D, Gauntlett C, Heumann LV, Kramer R, Marsden MD, Murray D, Chun TW, Zack JA, Wender PA. 2013. Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc Natl Acad Sci U S A 110:11698-11703. https://doi.org/10.1073/pnas.1302634110.
54. Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, Eron J, Cohen M, Margolis DM. 2010. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One 5:e9390. https://doi.org/10.1371/journal.pone.0009390.
55. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485. https://doi.org/10.1038/nature11286.
56. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S, Dinarello C, Buzon M, Lichterfeld M, Lewin SR, Ostergaard L, Sogaard OS. 2014. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1:e13-e21. https://doi.org/10.1016/S2352-3018(14)70014-1.
57. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366:549-555. https://doi.org/10.1016/S0140-6736(05)67098-5.
58. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF. 2012. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36:491-501. https://doi.org/10.1016/j.immuni.2012.01.014.
59. Ke R, Lewin SR, Elliott JH, Perelson AS. 2015. Modeling the effects of vorinostat in vivo reveals both transient and delayed HIV transcriptional activation and minimal killing of latently infected cells. PLoS Pathog 11:e1005237. https://doi.org/10.1371/journal.ppat.1005237.
60. Vranjkovic A, Crawley AM, Patey A, Angel JB. 2011. IL-7-dependent STAT-5 activation and CD8+ T cell proliferation are impaired in HIV infection. J Leukoc Biol 89:499-506. https://doi.org/10.1189/jlb.0710430.
61. Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE, Osborne CM, Hallahan CW, Cogliano-Shutta NA, Metcalf JA, McLaughlin M, Kwan R, Mican JM, Davey RT, Jr, Connors M. 2009. Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol 83:11876-11889. https://doi.org/10.1128/JVI.01153-09.
62. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavell RA, Shan L, Siliciano RF. 2015. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517:381-385. https://doi.org/10.1038/nature14053.
63. Sabado RL, O'Brien M, Subedi A, Qin L, Hu N, Taylor E, Dibben O, Stacey A, Fellay J, Shianna KV, Siegal F, Shodell M, Shah K, Larsson M, Lifson J, Nadas A, Marmor M, Hutt R, Margolis D, Garmon D, Markowitz M, Valentine F, Borrow P, Bhardwaj N. 2010. Evidence of dysregulation of dendritic cells in primary HIV infection. Blood 116:3839-3852. https://doi.org/10.1182/blood-2010-03-273763.
64. Buisson S, Benlahrech A, Gazzard B, Gotch F, Kelleher P, Patterson S. 2009. Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10. J Infect Dis 199:1862-1871. https://doi.org/10.1086/599122.
65. Majumder B, Janket ML, Schafer EA, Schaubert K, Huang XL, Kan-Mitchell J, Rinaldo CR, Jr, Ayyavoo V. 2005. Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape. J Virol 79:7990-8003. https://doi.org/10.1128/JVI.79.13.7990-8003.2005.
66. Winckelmann AA, Munk-Petersen LV, Rasmussen TA, Melchjorsen J, Hjelholt TJ, Montefiori D, Ostergaard L, Sogaard OS, Tolstrup M. 2013. Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS One 8:e62074. https://doi.org/10.1371/journal.pone.0062074.
67. Schlaepfer E, Speck RF. 2011. TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-alpha. J Immunol 186:4314-4324. https://doi.org/10.4049/jimmunol.1003174.
68. Novis CL, Archin NM, Buzon MJ, Verdin E, Round JL, Lichterfeld M, Margolis DM, Planelles V, Bosque A. 2013. Reactivation of latent HIV-1 in central memory CD4(+) T cells through TLR-1/2 stimulation. Retrovirology 10:119. https://doi.org/10.1186/1742-4690-10-119.
69. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6:769-776. https://doi.org/10.1038/ni1223.
70. Schlaepfer E, Rochat MA, Duo L, Speck RF. 2014. Triggering TLR2,-3,-4,-5, and-8 reinforces the restrictive nature of M1-and M2-polarized macrophages to HIV. J Virol 88:9769-9781. https://doi.org/10.1128/JVI.01053-14.
71. Schlaepfer E, Speck RF. 2008. Anti-HIV activity mediated by natural killer and CD8+ cells after Toll-like receptor 7/8 triggering. PLoS One 3:e1999. https://doi.org/10.1371/journal.pone.0001999.
72. Schlaepfer E, Audige A, Joller H, Speck RF. 2006. TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. J Immunol 176:2888-2895. https://doi.org/10.4049/jimmunol.176.5.2888.
73. Brichacek B, Vanpouille C, Kiselyeva Y, Biancotto A, Merbah M, Hirsch I, Lisco A, Grivel JC, Margolis L. 2010. Contrasting roles for TLR ligands in HIV-1 pathogenesis. PLoS One 5:e12831. https://doi.org/10.1371/journal.pone.0012831.
74. Salaun B, Romero P, Lebecque S. 2007. Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol 37:3311-3318. https://doi.org/10.1002/eji.200737744.
75. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, Vanhulle C, Lamine A, Vaira D, Demonte D, Martinelli V, Veithen E, Cherrier T, Avettand V, Poutrel S, Piette J, de Launoit Y, Moutschen M, Burny A, Rouzioux C, De Wit S, Herbein G, Rohr O, Collette Y, Lambotte O, Clumeck N, Van Lint C. 2009. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 4:e6093. https://doi.org/10.1371/journal.pone.0006093.
76. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, Siliciano JD, Siliciano RF. 2015. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125:1901-1912. https://doi.org/10.1172/JCI80142.
77. Hirano N, Butler MO, Xia Z, Ansen S, von Bergwelt-Baildon MS, Neuberg D, Freeman GJ, Nadler LM. 2006. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood 107:1528-1536. https://doi.org/10.1182/blood-2005-05-2073.
78. Chatillon JF, Hamieh M, Bayeux F, Abasq C, Fauquembergue E, Drouet A, Guisier F, Latouche JB, Musette P. 2015. Direct Toll-like receptor 8 signaling increases the functional avidity of human CD8+ T lymphocytes generated for adoptive T cell therapy strategies. Immun Inflamm Dis 3:1-13. https://doi.org/10.1002/iid3.43.
79. Serbina NV, Salazar-Mather TP, Biron CA, Kuziel WA, Pamer EG. 2003. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19:59-70. https://doi.org/10.1016/S1074-7613(03)00171-7.
80. Xu Y, Zhan Y, Lew AM, Naik SH, Kershaw MH. 2007. Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J Immunol 179: 7577-7584. https://doi.org/10.4049/jimmunol.179.11.7577.
81. Robbins SH, Walzer T, Dembele D, Thibault C, Defays A, Bessou G, Xu H, Vivier E, Sellars M, Pierre P, Sharp FR, Chan S, Kastner P, Dalod M. 2008. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol 9:R17. https://doi.org/10.1186/gb-2008-9-1-r17.
82. Jordan A, Bisgrove D, Verdin E. 2003. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22: 1868-1877. https://doi.org/10.1093/emboj/cdg188.
83. Simpson TR, Quezada SA, Allison JP. 2010. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol 22:326-332. https://doi.org/10.1016/j.coi.2010.01.001.
84. Witsch EJ, Peiser M, Hutloff A, Buchner K, Dorner BG, Jonuleit H, Mages HW, Kroczek RA. 2002. ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. Eur J Immunol 32:2680-2686. https://doi.org/10.1002/1521-4141(200209)32:9<2680::AID-IMMU2680>3.0.CO;2-6.
85. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V. 2013. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 9:e1003834. https://doi.org/10.1371/journal.ppat.1003834.
86. Williams SA, Kwon H, Chen LF, Greene WC. 2007. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol 81:6043-6056. https://doi.org/10.1128/JVI.02074-06.
87. Ahmed AU, Williams BR, Hannigan GE. 2015. Transcriptional activation of inflammatory genes: mechanistic insight into selectivity and diversity. Biomolecules 5:3087-3111. https://doi.org/10.3390/biom5043087.
88. Katan-Khaykovich Y, Struhl K. 2002. Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone acetylation status upon removal of activators and repressors. Genes Dev 16:743-752. https://doi.org/10.1101/gad.967302.
89. Yu T, Yi YS, Yang Y, Oh J, Jeong D, Cho JY. 2012. The pivotal role of TBK1 in inflammatory responses mediated by macrophages. Mediators Inflamm 2012:979105. https://doi.org/10.1155/2012/979105.
90. Lin YC, Huang DY, Chu CL, Lin YL, Lin WW. 2013. The tyrosine kinase Syk differentially regulates Toll-like receptor signaling downstream of the adaptor molecules TRAF6 and TRAF3. Sci Signal 6:ra71. https://doi.org/10.1126/scisignal.2003973.
91. Darcis G, Bouchat S, Kula A, Van Driessche B, Delacourt N, Vanhulle C, Avettand-Fenoel V, De Wit S, Rohr O, Rouzioux C, Van Lint C. 14 October 2016. Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir. AIDS https://doi.org/10.1097/QAD.0000000000001290.
92. Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, Nastouli E, Tanwar S, Rosenberg W, Maini MK. 2013. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog 9:e1003208. https://doi.org/10.1371/journal.ppat.1003208.
93. Halwani R, Boyer JD, Yassine-Diab B, Haddad EK, Robinson TM, Kumar S, Parkinson R, Wu L, Sidhu MK, Phillipson-Weiner R, Pavlakis GN, Felber BK, Lewis MG, Shen A, Siliciano RF, Weiner DB, Sekaly RP. 2008. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol 180:7969-7979. https://doi.org/10.4049/jimmunol.180.12.7969.
94. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-551. https://doi.org/10.1016/j.cell.2013.09.020.
95. Leon B, Lopez-Bravo M, Ardavin C. 2007. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26:519-531. https://doi.org/10.1016/j.immuni.2007.01.017.
96. Fernandez G, Zeichner SL. 2010. Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol J 7:266. https://doi.org/10.1186/1743-422X-7-266.
97. Akimova T, Beier UH, Liu Y, Wang L, Hancock WW. 2012. Histone/protein deacetylases and T-cell immune responses. Blood 119: 2443-2451. https://doi.org/10.1182/blood-2011-10-292003.
98. Gulakowski RJ, McMahon JB, Buckheit RW, Jr, Gustafson KR, Boyd MR. 1997. Antireplicative and anticytopathic activities of prostratin, a nontumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res 33:87-97. https://doi.org/10.1016/S0166-3542(96)01004-2.
99. Pauls E, Ruiz A, Riveira-Munoz E, Permanyer M, Badia R, Clotet B, Keppler OT, Ballana E, Este JA. 2014. p21 regulates the HIV-1 restriction factor SAMHD1. Proc Natl Acad Sci U S A 111:E1322-E1324. https://doi.org/10.1073/pnas.1322059111.
100. Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, Carrington MF, Porter LC, Burke PS, Yang Y, Ryan BJ, Liu R, Weiss RH, Pereyra F, Cress WD, Brass AL, Rosenberg ES, Walker BD, Yu XG, Lichterfeld M. 2011. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 121:1549-1560. https://doi.org/10.1172/JCI44539.
101. Gane EJ, Lim YS, Gordon SC, Visvanathan K, Sicard E, Fedorak RN, Roberts S, Massetto B, Ye Z, Pflanz S, Garrison KL, Gaggar A, Mani Subramanian G, McHutchison JG, Kottilil S, Freilich B, Coffin CS, Cheng W, Kim YJ. 2015. The oral Toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol 63:320-328. https://doi.org/10.1016/j.jhep.2015.02.037.
102. Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, Meng TC. 2007. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 47:174-182. https://doi.org/10.1016/j.jhep.2007.02.025.
103. Mandraju R, Murray S, Forman J, Pasare C. 2014. Differential ability of surface and endosomal TLRs to induce CD8 T cell responses in vivo. J Immunol 192:4303-4315. https://doi.org/10.4049/jimmunol.1302244.
104. Perez VL, Rowe T, Justement JS, Butera ST, June CH, Folks TM. 1991. An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation. J Immunol 147:3145-3148.
105. Beadling C, Slifka MK. 2005. Differential regulation of virus-specific T-cell effector functions following activation by peptide or innate cytokines. Blood 105:1179-1186.
106. Keppler SJ, Aichele P. 2011. Signal 3 requirement for memory CD8+ T-cell activation is determined by the infectious pathogen. Eur J Immunol 41:3176-3186. https://doi.org/10.1002/eji.201141537.
107. Ramos HJ, Davis AM, Cole AG, Schatzle JD, Forman J, Farrar JD. 2009. Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates. Blood 113:5516-5525. https://doi.org/10.1182/blood-2008-11-188458.
108. Trinchieri G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133-146. https://doi.org/10.1038/nri1001.
109. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC. 2014. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158:989-999. https://doi.org/10.1016/j.cell.2014.07.043.
110. Aicher A, Hayden-Ledbetter M, Brady WA, Pezzutto A, Richter G, Magaletti D, Buckwalter S, Ledbetter JA, Clark EA. 2000. Characterization of human inducible costimulator ligand expression and function. J Immunol 164:4689-4696. https://doi.org/10.4049/jimmunol.164.9.4689.
111. van der Sluis RM, van Montfort T, Pollakis G, Sanders RW, Speijer D, Berkhout B, Jeeninga RE. 2013. Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes. PLoS Pathog 9:e1003259. https://doi.org/10.1371/journal.ppat.1003259.
112. Mobley JL, Ennis E, Shimizu Y. 1994. Differential activation-dependent regulation of integrin function in cultured human T-leukemic cell lines. Blood 83:1039-1050.
113. Zhou C, Ji J, Shi M, Yang L, Yu Y, Liu B, Zhu Z, Zhang J. 2014. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin induced Src activation in gastric cancer cells. Mol Med Rep 10:2729-2735. https://doi.org/10.3892/mmr.2014.2548.
114. Kai L, Samuel SK, Levenson AS. 2010. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int J Cancer 126:1538-1548. https://doi.org/10.1002/ijc.24928.
115. Agalioti T, Chen G, Thanos D. 2002. Deciphering the transcriptional histone acetylation code for a human gene. Cell 111:381-392. https://doi.org/10.1016/S0092-8674(02)01077-2.
116. Mahmoudi T, Parra M, Vries RG, Kauder SE, Verrijzer CP, Ott M, Verdin E. 2006. The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J Biol Chem 281:19960-19968. https://doi.org/10.1074/jbc.M603336200.
117. Van Lint C, Emiliani S, Ott M, Verdin E. 1996. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15:1112-1120.
118. Shahbazian MD, Grunstein M. 2007. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 76:75-100. https://doi.org/10.1146/annurev.biochem.76.052705.162114.
119. Kim YK, Mbonye U, Hokello J, Karn J. 2011. T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway. J Mol Biol 410:896-916. https://doi.org/10.1016/j.jmb.2011.03.054.
120. Takada Y, Aggarwal BB. 2004. TNF activates Syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF-kappaB activation, and apoptosis. J Immunol 173:1066-1077. https://doi.org/10.4049/jimmunol.173.2.1066.
121. Mocsai A, Ruland J, Tybulewicz VL. 2010. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 10: 387-402. https://doi.org/10.1038/nri2765.
122. Chauhan AK, Moore TL. 2012. Immune complexes and late complement proteins trigger activation of Syk tyrosine kinase in human CD4(+) T cells. Clin Exp Immunol 167:235-245. https://doi.org/10.1111/j.1365-2249.2011.04505.x.
123. Grammatikos AP, Ghosh D, Devlin A, Kyttaris VC, Tsokos GC. 2013. Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling. PLoS One 8:e74550. https://doi.org/10.1371/journal.pone.0074550.
124. Fujinaga K, Barboric M, Li Q, Luo Z, Price DH, Peterlin BM. 2012. PKC phosphorylates HEXIM1 and regulates P-TEFb activity. Nucleic Acids Res 40:9160-9170. https://doi.org/10.1093/nar/gks682.
125. Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384. https://doi.org/10.1038/ni.1863.
126. Law CL, Sidorenko SP, Chandran KA, Zhao Z, Shen SH, Fischer EH, Clark EA. 1996. CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation. J Exp Med 183:547-560. https://doi.org/10.1084/jem.183.2.547.
127. Jiang Y, Cheng H. 2007. Evidence of LAT as a dual substrate for Lck and Syk in T lymphocytes. Leuk Res 31:541-545. https://doi.org/10.1016/j.leukres.2006.07.010.
128. Fromentin R, Bakeman W, Lawani MB, Khoury G, Hartogensis W, Da-Fonseca S, Killian M, Epling L, Hoh R, Sinclair E, Hecht FM, Bacchetti P, Deeks SG, Lewin SR, Sekaly RP, Chomont N. 2016. CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART. PLoS Pathog 12:e1005761. https://doi.org/10.1371/journal.ppat.1005761.
129. Vignali DA. 2000. Multiplexed particle-based flow cytometric assays. J Immunol Methods 243:243-255. https://doi.org/10.1016/S0022-1759(00)00238-6.